 Home > Active Ingredient News > Antitumor Therapy > Int J Urol: The impact of platinum-based first-line chemotherapy on the overall survival of patients with metastatic urothelial carcinoma

Int J Urol: The impact of platinum-based first-line chemotherapy on the overall survival of patients with metastatic urothelial carcinoma

 Last Update: 2021-11-02
 Source: Internet
 Author: User

Tags

2 4 dimethylphenol

unmc cancer center

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Pembrolizumab is a monoclonal antibody to PD-L1, which can improve the overall survival (OS) of patients with advanced or metastatic UC who are resistant to platinum-based chemotherapy
.

According to reports, compared with single-agent chemotherapy, Pembrolizumab can prolong OS by about 3 months and delay the onset of deterioration in quality of life

However , how many cycles of chemotherapy should be performed before using immune checkpoint inhibitors.

Recently, researchers from Japan published an article in Int J Urol, investigating the effect of the number of cycles of chemotherapy and the objective response on the overall survival of patients with metastatic urinary tract cancer treated with pembrolizumab
.

The effects of the number of cycles of chemotherapy and the objective response on the overall survival of patients with metastatic urinary tract cancer treated with pembrolizumab were investigated
.

The effects of the number of cycles of chemotherapy and the objective response on the overall survival of patients with metastatic urinary tract cancer treated with pembrolizumab were investigated

The study was a multi-center retrospective study, including 755 patients with advanced, chemotherapy-resistant urothelial cancer treated with pembrolizumab from 59 institutions
.

Cox multiple regression analysis was used to explore the relationship between overall survival and the number of chemotherapy cycles and the best objective response

In total, 391 patients received standard first-line chemotherapy and second-line pembrolizumab and were included in the final analysis
.

Of the 391 patients, 185 received less than four cycles of chemotherapy, 134 received four to six cycles, and 72 received more than six cycles

Kaplan-Meier curve analysis of overall survival

In summary, regardless of the objective response and cycle number of first-line platinum-based chemotherapy, there is no effect on the overall survival of pembrolizumab treatment

Regardless of the objective response and cycle number of first-line platinum-based chemotherapy, it has no effect on the overall survival of pembrolizumab treatment.

Original source:

Minoru Kato, Takashi Kobayashi, Yoshiyuki Matsui et al.

Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.